Statin-associated muscle adverse events

Update for clinicians

Maha A. Al-Mohaissen, Martha J. Ignaszewski, Jiri Frohlich, Andrew P. Ignaszewski

Research output: Contribution to journalReview articleResearchpeer-review

6 Citations (Scopus)

Abstract

Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.

Original languageEnglish
Pages (from-to)e406-e415
JournalSultan Qaboos University Medical Journal
Volume16
Issue number4
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Muscles
LDL Cholesterol
Guidelines
Risk Reduction Behavior
Physicians
Therapeutics

Keywords

  • Adverse effects
  • Hydroxymethylglutaryl-CoA reductase inhibitors
  • Hypercholesterolemia
  • Hyperlipidemias
  • Myopathies

Cite this

Al-Mohaissen, Maha A. ; Ignaszewski, Martha J. ; Frohlich, Jiri ; Ignaszewski, Andrew P. / Statin-associated muscle adverse events : Update for clinicians. In: Sultan Qaboos University Medical Journal. 2016 ; Vol. 16, No. 4. pp. e406-e415.
@article{568d627c0a3e48feafdcfaeb2d947a39,
title = "Statin-associated muscle adverse events: Update for clinicians",
abstract = "Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.",
keywords = "Adverse effects, Hydroxymethylglutaryl-CoA reductase inhibitors, Hypercholesterolemia, Hyperlipidemias, Myopathies",
author = "Al-Mohaissen, {Maha A.} and Ignaszewski, {Martha J.} and Jiri Frohlich and Ignaszewski, {Andrew P.}",
year = "2016",
month = "11",
day = "1",
doi = "10.18295/squmj.2016.16.04.002",
language = "English",
volume = "16",
pages = "e406--e415",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "4",

}

Statin-associated muscle adverse events : Update for clinicians. / Al-Mohaissen, Maha A.; Ignaszewski, Martha J.; Frohlich, Jiri; Ignaszewski, Andrew P.

In: Sultan Qaboos University Medical Journal, Vol. 16, No. 4, 01.11.2016, p. e406-e415.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Statin-associated muscle adverse events

T2 - Update for clinicians

AU - Al-Mohaissen, Maha A.

AU - Ignaszewski, Martha J.

AU - Frohlich, Jiri

AU - Ignaszewski, Andrew P.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.

AB - Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.

KW - Adverse effects

KW - Hydroxymethylglutaryl-CoA reductase inhibitors

KW - Hypercholesterolemia

KW - Hyperlipidemias

KW - Myopathies

UR - http://www.scopus.com/inward/record.url?scp=85001022574&partnerID=8YFLogxK

U2 - 10.18295/squmj.2016.16.04.002

DO - 10.18295/squmj.2016.16.04.002

M3 - Review article

VL - 16

SP - e406-e415

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 4

ER -